hotspot -WSS

hotspot

author：entertainment 2025-09-28 01:40:08 - browse：27

In a surprise move, the Food and Drug Administration has called for a meeting of outside advisers to discuss whether an Alzheimer’s drug from Eli Lilly should be approved, even as many outsiders expected the medicine to receive regulatory clearance this month.

The drug, donanemab, succeeded in its Phase 3 trial, resulting in a 35% slowing of Alzheimer’s disease progression versus placebo. But Lilly on Friday said that the FDA expects to call a meeting of an advisory committee to review the trial, saying that the agency had told the company “it wants to further understand topics related to evaluating the safety and efficacy of donanemab, including the safety results in donanemab-treated patients and the efficacy implications of the unique trial design” of the study.

A date for the meeting has not been set yet.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Why Medicare shouldn’t cover every FDA

hotspot

entertainment

WSS

Why Medicare shouldn’t cover every FDA

The Affordable Care Act has saved billions in health care costs

The Affordable Care Act has saved billions in health care costs

Boston competes with Raleigh

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Pancreatic cancer early detection could be helped by AI

hotspot

hotspot

hotspot

Trump demands the U.S. pay no more for drugs than other countries … again

With trial win, GSK could get blood cancer drug back on market

How one medical school became remarkably diverse

Vertex non

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Reconstructing family trees of blood cells may help predict disease

Medical records are filled with copy

Investment in vaccine development is lagging, report finds

How one medical school became remarkably diverse

Boston competes with Raleigh

knowledge

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Reconstructing family trees of blood cells may help predict disease

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Vertex non

Boston competes with Raleigh

entertainment

explore

knowledge

focus